Eli Lilly’s weekly insulin intensifies race with Novo Nordisk

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company’s race with Novo Nordisk to develop longer-acting insulins.

Please leave this field empty

Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox, every month.

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.